Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure

Murphy, Kevin R.; Chipps, Bradley E.; Beuther, David A.; Wise, Robert A.; McCann, William; Gilbert, Ileen; Eudicone, James M.; Gandhi, Hitesh; Harding, Gale; Coyne, Karin S.; Zeiger, Robert S.; Kobernick, Aaron K.; Mohammad, Acklema; Cherry, Adam T.; Fein, Alan M.; Gaines, Alan; Ramsey, Allison; Michaud, Amanda L.; A, Palmer; Kim, Andrew S.; Smith, Andrew M.; White, Andrew A.; Ricci, Anthony R.; Kettelhut, Brett; Modena, Brian D.; Stone, Brian; Rolston, B. Steele; Schnapf, Bruce M.; Krajicek, Bryan J.; Kraft, Cara; Hopkins, Carly; Natalie, Chitra R; Anderson, Christine T.; Czajkowski, Christine; Arce, Daisy; Hamlin, Danuel; Hill, David; Mares, David C.; Pham, David; Liao, Da-Wei; Simmons, Deborah C.; Johnson, Derek K.; Jhaveri, Devi; Maselli, Diego J.; Kerwin, Edward; Schuman, Edward; Sher, Ellen; Bleecker, Eugene R.; Rakowski, Ewa; Hsu, Florence Ida; Averill, Francis; Barsanti, Franco; Gross, Gary N.; Chupp, Geoffrey; Head, G. Gilbert; Nasir, Hassan; Lee, Howard J.; Barjaktarević, Igor; Cook, J. Paul; Krainson, James; Pearl, James; Bellak, J.M.; Perez-Fernandez, Javier; Rehm, Jeffrey; Trevor, Jennifer; Most, Jessica; Hanson, Jill; Blessing-Moore, Joann; Biller, Jodi H.; Gedell, John; Southard, John; Chancellor, Jon Eric; Ilowite, Jonathan S.; Romeo, Jonathan; Mercado, Jorge M.; Fisher, Joseph Dominic; Greiwe, Justin; Gregory, Karen; Nadeau, Kari; Shenoy, Kartik; Tan, Laren; Stefanowicz, Leslie A.; Humes, Lindsay D.; Bowers, Lori; O’Connor, Maeve Edel; Perez, Mario F.; White, Martha V.; Hegewald, Matthew; Wilson, Matthew Charles; Sikora, Maxcie M.; Morganroth, Melvin L.; Smith, Mitchell R.; Farooqui, Nabeel; Lesch, Nathan James; Jain, Neal; Parikh, N.; Hartog, Nicholas; Luthin, Patricia L.; Stewart, Praphaporn; O’Connor, Peggy Rubio; Schochet, Peter Z.; Goldberg, Pinkus; Patel, Pulin P.; Chinthrajah, R. Sharon; Sidhu, Rabinder; Ayinla, Raji; Brown, Randall W.; Stadtler, Reneé; Wachs, Richard; Balkissoon, Ronald; Duplantier, Rory L.; Puente, Rosalba E.; Settipane, Russell A.; Mustafa, S. Shahzad; Surani, Salim; Jawad, Sami Abdul; Adams, Sandra G.; Villegas, Sarah; Al-Farra, Sherif; Subramanian, Shyamsunder; Bains, Sonia N.; Kelsen, Steven G.; Wise, Steven L.; Estrella-Eades, Susan; Smith, Susan M.; Qureshi, Tabarak; Chen, Taiwen; Kelbel, Theodore; Miller, Thomas P.; Jain, Vipin; Soong, Weily; Soler, Xavier; Mattar, Ziad

doi:10.1016/j.jaip.2020.02.042

Cited by 42 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…impairment but not risk) and thus fail to measure important aspects of the disease (e.g. OCS use) [51]. Additionally, the ACQ was initially developed to assess clinically important differences in asthma control at the individual level (e.g.…”

Section: Discussionmentioning

confidence: 99%

“…Ultimately, future ideations of consensus definitions for clinical remission in severe asthma could incorporate a different or more comprehensive PRO assessment of asthma control, such as the Asthma Impairment and Risk Questionnaire (AIRQ) or the Predominant Symptom and Impairment Assessment (PSIA) [51,53]. Furthermore, regardless of clinical improvements, patients with a long history of asthma may not score as ''normal'' on the ACQ because of the presence of chronic symptoms, side effects from long-term OCS use, or other comorbidities.…”

Section: Discussionmentioning

confidence: 99%

“…Likewise, as discussed earlier, although other PRO tools (e.g. AIRQ or PSIA) may ultimately provide additional, and possibly more accurate, insights into levels of symptom control among patients with severe asthma, only ACQ-6 absolute scores were available from the benralizumab pivotal trials, which is why they were used for this post hoc analysis [51,53]. Finally, despite our efforts to identify similar patient populations between all three studies, differences between the trial designs (e.g.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

et al. 2022

View full text Add to dashboard Cite

Introduction: Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor a-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite remission definition to characterize individual responses to benralizumab after 6 and 12 months. Methods: In previous phase 3 studies, eligible patients were those with severe, uncontrolled asthma receiving medium-or high-dosage inhaled corticosteroids plus long-acting b 2 -agonists. This post hoc analysis included patients randomized to the approved benralizumab dose and not receiving oral corticosteroids (OCS) at baseline (SIROCCO/CALIMA) or OCS B 12.5 mg per day (ZONDA). Individual remission components were zero exacerbations; zero OCS use; Asthma Control Questionnaire-6

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

et al. 2022

View full text Add to dashboard Cite

show abstract

“…U.S. patients and HCPs tend to underestimate the consequences of asthma symptoms, 39 relying predominantly on SABA for rapid relief. 28,40 These findings suggest the need for ICS administration, either as regular maintenance treatment or intermittently, to address variability in airway inflammation in SABA monotherapyetreated patients and lend support to the GINA recommendation of not distinguishing intermittent from mild persistent asthma.…”

Section: Clinically Relevant Similarities and Differences For The Uni...mentioning

confidence: 99%

Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America

Quint

Arnetorp

Kocks

et al. 2022

The Journal of Allergy and Clinical Immunology: In Practice

Self Cite

View full text Add to dashboard Cite

“…This is supported by the findings in the current analysis that patients with physician-assessed mild asthma can have severe exacerbations, and even exacerbations among those with well controlled asthma symptoms in the previous 4 weeks. Consequently, it would be interesting to assess the recently developed Asthma Impairment and Risk Questionnaire [37], which includes both asthma symptom control and exacerbation risk together, in patients with mild asthma.…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

Golam

Beasley

Harrison

et al. 2022

Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure

Cited by 42 publications

References 38 publications

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America

The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

Contact Info

Product

Resources

About